Dasolampanel (NGX-426) is an orally available competitive antagonist of the AMPA and kainate receptors. The dug originated at Eli Lilly and Horizon Pharma and was developed for the treatment of migraine and neuropathic pain. Dasalompanel was reduced capsaicin-induced pain and hyperalgesia in human volunteers but failed to achieve positive results in phase 2 clinical trials in patients with pain due to osteoarthritis of the knee and diabetic peripheral neuropathic pain.

Besifovir (also known as LB80331), an active metabolite of LB80380 was studied for the treatment of hepatitis B.

Chlorothalonil (2,4,5,6-tetrachloroisophthalonitrile) is an organic compound mainly used as a broad spectrum, nonsystemic fungicide, with other uses as a wood protectant, pesticide, acaricide, and to control mold, mildew, bacteria, algae. Chlorothalonil reduces fungal intracellular glutathione molecules to alternate forms which cannot participate in essential enzymatic reactions, ultimately leading to cell death. Chlorothalonil is slightly toxic to mammals, but it can cause severe eye and skin irritation in certain formulations. Very high doses may cause a loss of muscle coordination, rapid breathing, nose bleeding, vomiting, and hyperactivity. Dermatitis, vaginal bleeding, bright yellow and/or bloody urine, and kidney tumors may also occur, followed by death. In a number of tests of varying lengths of time, rats which were fed a range of doses of chlorothalonil generally showed no effects on physical appearance, behavior, or survival. Kidney changes such as kidney enlargement were common. In the US, chlorothalonil is used predominantly on peanuts (about 34% of usage), potatoes (about 12%), and tomatoes (about 7%), though the EPA recognizes its use on many other crops. It is also used on golf courses and lawns (about 10%) and as a preservative additive in some paints (about 13%), resins, emulsions, and coatings. Chlorothalonil is commercially available in many different formulations and delivery methods. It is applied as a dust, dry or water-soluble grains, a wettable powder, a liquid spray, a fog, and a dip. It may be applied by hand, by ground sprayer, or by aircraft

Glyceryl trierucate (trierucin) is a trierucic acid triglyceride that has been investigated for the treatment of adrenoleukodystrophy, a rare genetic disorder characterized by the breakdown or loss of myelin in the brain. To investigate treatment options for adrenoleukodystrophy, most studies have used “Lorenzo's oil" (LO), a 4:1 mixture of glyceryl trioleate and glyceryltrierucate. Lorenzo’s oil was found to reduce the levels of saturated very long chain fatty acids (ELOVL) in the plasma, adipose tissue and liver, but to a lesser extent in the brain. Inhibition of ELOVL 1 may be an underlying mechanism by which Lorenzo's oil exerts its action. Several clinical trials have been conducted to study the potential of glyceryl trierucate in treatment of adrenoleukodystrophy.

Sodium tripolyphosphate hexahydrate (sodium trimetaphosphate) is used in laundry detergent as a detergent "builder". It may also be used as a buffering agent. It has been shown that fluoride varnishes containing sodium trimetaphosphate reduce enamel demineralization. Sodium trimetaphosphate enhances the effect of 250 p.p.m. fluoride toothpaste against enamel demineralization in vitro. It also demonstrated significant antimicrobial activity, especially against S. mutans, and may be considered a potential alternative for new dental materials.

AZD1305, an antiarrhythmic agent, blocks the hERG potassium channel, the L-type calcium, and the Sodium channel protein Nav1.5. AZD1305 participated in clinical trials for the management of atrial fibrillation and Left ventricular dysfunction. The benefit-risk profile was judged as unfavorable and the AZD1305 development programme was discontinued.

AZD-1981, developed by AstraZeneca, is a potent (binding IC50 of 4nM), fully reversible, functionally non-competitive antagonist of human CRTh2. It blocks agonist-induced human eosinophil CD11b expression, shape change (including in whole blood), and chemotaxis as well as an basophil shape change and Th2-cell chemotaxis at IC50's of 8.5-50nM. Potency is similar across species as is plasma protein binding (~97%). AZD-1981 is a weak (10s of μM) inhibitor in vitro of CYP2C9, OATP1B1 and UGT1A1 as well as an inducer of CYP3A4. AZD-1981 was well tolerated and no safety concerns were identified.There was no beneficial clinical effect of AZD-1981, at a dose of 1000 mg twice daily for 4 weeks, in patients with moderate to severe COPD. AZD-1981 has being discontinued for asthma and chronic obstructive pulmonary disease. AstraZeneca is collaborating with Johns Hopkins University for the development of AZD-1981 in the treatment of chronic idiopathic urticaria. It is in phase II clinicals studies for the treatment of Urticaria.

Simenepag (AGN-210676) is a a small molecule selective prostaglandin EP2 agonist with EC50 of 5 nM. Allergan was developing simenepag for the treatment of glaucoma and ocular hypertension.